[Pharmacological studies on a new penicillin group antibiotic, sodium 6-[D(-)-alpha-(4-ethyl-2, 3-dioxo-1-piperazinecarboxamido)-alpha-phenylacetamido] penicillanate (T-1220). III. Effect on smooth-muscle organs (author's transl)].
D000667:Ampicillin / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000187:drug effects; D001646:Bile / Q000378:metabolism; D002415:Cats; D002802:Cholinesterases / Q000378:metabolism; D003106:Colon / Q000187:drug effects; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009130:Muscle, Smooth / Q000187:drug effects*; D009541:Nictitating Membrane / Q000187:drug effects; D010406:Penicillins / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology; D011680:Pupil / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D013270:Stomach / Q000187:drug effects; D014132:Trachea / Q000187:drug effects; D014599:Uterus / Q000187:drug effects; D014649:Vas Deferens / Q000187:drug effects
D010406:Penicillins; D010879:Piperazines; D000667:Ampicillin; D002802:Cholinesterases